Is the new price right?: HTA takes a back seat to broader price negotiations
Our Blog
See below for an opinion on current matters around the world.
Could Human HTA Committees be Replaced with AI Systems?
WFH ... WTF ... ????: Working-from-home, employer reaction and pandemic-inspired industrial changes
Ghosts in the Machine: the search for productivity measures in health technology assessment
More ‘us’ and less ‘them’ thinking: a plea for 2024
Déjà vu all over again?: Australia’s industrial policy debate
Universal Health Coverage at the Half-Way Point: Political Disappointment & Business Opportunity
Have health and the PBS come of age as the Intergenerational Report turns 21?
Unconscious uncoupling?: Three years on Covid-19 is no longer a global emergency
The Magic, Myths & Fantasy of ESG: What Does it Mean for Pharma?
From the sublime to the ridiculous: 5 years of Shawview Consulting blogs
Species extinction in Australia: time for a wake-up call
Lessons learned: finance and resilience in post-COVID health systems
Jane Fonda, mix tapes & Australia's 5% discount rate: when time, health economics and ethics collide
It’s the economy, stupid: the economic benefits of health spending
Australians now understand there is a 'queue' for new health technologies
A little less conversation, a little more action please: the global state of AMR
What would Dr Who say?: Time travel and the macroeconomic impact of COVID-19
The economist, the activist and the epiphany: an argument about efficiency in health spending
Creeping Through the Backdoor: Disruption in Medicine and Health